11, found patients who were prescribed a GLP-1 to treat Type 2 diabetes had a slightly higher risk of developing diabetic retinopathy, but also a lower risk of progressing to sight-threatening complications or stages of the condition
Human research on peptide-related compounds shows that certain pathways can influence fat-free mass, growth hormone, IGF-1, and body composition, but results vary by compound, patient population, training status, nutrition, and medical context
sporadic adherence or frequent dose pauses reduce cumulative weight loss
A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity
Some degree of pain or discomfort during the process & for an average of 2-4 hours post treatment
Never reuse needles or needles, as this can prompt defilement and disease risk